We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Acadia is playing for keeps. It's not just about crushing 2025 sales recordsit's about building a powerhouse. With a strong lineup of innovative therapies, a clear path to European revenues, and some ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) and keeping the price ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a decline, ending the day at $16.9 which represents a decrease of $-1.00 or -5.59% from the prior close of $17.9. The stock opened at $18.15 and touched a ...

Fintel reports that on January 3, 2025, Guggenheim downgraded their outlook for ACADIA Pharmaceuticals (NasdaqGS:ACAD) from ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

Diversified Trust Co boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 9.8% during the fourth ...

During five years of share price growth, ACADIA Pharmaceuticals moved from a loss to profitability. That would generally be considered a positive, so we are surprised to see the share price is down.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating ...